OHR Pharmaceutical Inc. (OHRP)’s Financial Results Comparing With RedHill Biopharma Ltd. (NASDAQ:RDHL)

This is therefore a contrasting of the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation in OHR Pharmaceutical Inc. (NASDAQ:OHRP) and RedHill Biopharma Ltd. (NASDAQ:RDHL). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OHR Pharmaceutical Inc. N/A 0.00 9.98M -3.54 0.00
RedHill Biopharma Ltd. 8.36M 28.96 38.82M -1.70 0.00

Demonstrates OHR Pharmaceutical Inc. and RedHill Biopharma Ltd. earnings per share, top-line revenue and valuation.


Table 2 has OHR Pharmaceutical Inc. and RedHill Biopharma Ltd.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
OHR Pharmaceutical Inc. 0.00% -71.5% -66.8%
RedHill Biopharma Ltd. -464.35% 0% 0%

Analyst Recommendations

The table given features the ratings and recommendations for OHR Pharmaceutical Inc. and RedHill Biopharma Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
OHR Pharmaceutical Inc. 0 0 0 0.00
RedHill Biopharma Ltd. 0 0 2 3.00

RedHill Biopharma Ltd. on the other hand boasts of a $16.5 average price target and a 96.90% potential upside.

Institutional & Insider Ownership

OHR Pharmaceutical Inc. and RedHill Biopharma Ltd. has shares held by institutional investors as follows: 12.7% and 29.11%. 8.89% are OHR Pharmaceutical Inc.’s share held by insiders. Competitively, 19.1% are RedHill Biopharma Ltd.’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OHR Pharmaceutical Inc. 3.29% -17.91% -31.21% -43.18% -50.81% 27.91%
RedHill Biopharma Ltd. -1.67% -7.59% -6.35% 2.68% 19.47% 38.2%

For the past year OHR Pharmaceutical Inc. was less bullish than RedHill Biopharma Ltd.


On 7 of the 10 factors RedHill Biopharma Ltd. beats OHR Pharmaceutical Inc.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. Its clinical-stage pipeline includes TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two European Union member states under the European Decentralized Procedure. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.